Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $42.0 million.

  • Arcus Biosciences' Accounts Payables rose 22307.69% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year increase of 22307.69%. This contributed to the annual value of $18.0 million for FY2024, which is 588.24% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Accounts Payables is $42.0 million, which was up 22307.69% from $29.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Accounts Payables ranged from a high of $42.0 million in Q3 2025 and a low of $10.0 million during Q4 2021
  • Over the past 5 years, Arcus Biosciences' median Accounts Payables value was $17.0 million (recorded in 2023), while the average stood at $19.2 million.
  • In the last 5 years, Arcus Biosciences' Accounts Payables skyrocketed by 91170.65% in 2021 and then crashed by 4541.48% in 2023.
  • Over the past 5 years, Arcus Biosciences' Accounts Payables (Quarter) stood at $10.0 million in 2021, then surged by 100.0% to $20.0 million in 2022, then decreased by 15.0% to $17.0 million in 2023, then increased by 5.88% to $18.0 million in 2024, then surged by 133.33% to $42.0 million in 2025.
  • Its Accounts Payables was $42.0 million in Q3 2025, compared to $29.0 million in Q2 2025 and $22.0 million in Q1 2025.